Publication:
Hepatitis C Virus Core Antigen As Alternative Diagnostic Algorithm For Active Hepatitis C Virus Infection Among Haemodialysis Population: Cost Implications

Simple item page
dc.contributor.authorXue Z. Wongen_US
dc.contributor.authorAmirah Azzerien_US
dc.contributor.authorChye C. Ganen_US
dc.contributor.authorShabaruddin Fatihaen_US
dc.contributor.authorDahlui Maznahen_US
dc.contributor.authorRosnawati Yahyaen_US
dc.contributor.authorShubash Ganapathyen_US
dc.contributor.authorSoek S. Tanen_US
dc.contributor.authorRosmawati Mohameden_US
dc.contributor.authorSoo K. Limen_US
dc.date.accessioned2024-05-28T08:42:08Z
dc.date.available2024-05-28T08:42:08Z
dc.date.issued2021
dc.date.submitted2022-1-3
dc.description.abstractAims: In Malaysia, majority anti-HCV positive haemodialysis patients do not undergo hepatitis C confirmation due to the high cost of HCV RNA. HCV Core Antigen might be a cost-effective diagnostic test to identify HD patients who have active HCV infection eligible for Direct Acting Anti-viral therapy. Methods: A cross-sectional study was conducted to assess the correlation between HCV Ag and HCV RNA and the cost implications of different diagnostic algorithms to diagnose active HCV infection using Anti-HCV, HCV Ag, and HCV RNA. Pre-dialysis blood was tested for both HCV Ag and HCV RNA. HCV Ag was tested with Abbott ARCHITECT HCV Ag test. Results: Two-hundred twenty-seven haemodialysis patients were recruited from 20 centres with mean age of 57.68 ± 12.48 years, and male constitutes 56.8% (129) of the study population. HCV Ag correlated well with HCV RNA (Spearman test coefficient 0.943, p < .001) with sensitivity of 93.9%, specificity 99.3%, and the accuracy was 97.36%. Cost analysis indicated that a sequential test involving Anti-HCV antibody as initial screening, followed by HCV Ag on Anti-HCV positive and HCV RNA on HCV Ag negative cases translated to a modest cost-saving algorithm compared to standard diagnostic algorithm. Conclusion: HCV Ag correlated well with HCV RNA and can potentially be fused in an alternative diagnostic algorithm to generate cost savings methods to diagnose active HCV infection among haemodialysis patients. This alternative algorithm is especially relevant in low to middle-income countries such as Malaysia to optimize the use of the healthcare resource and gains in clinical outcomes.en_US
dc.identifier.doi10.1111/nep.13862
dc.identifier.epage470
dc.identifier.issn1320-5358
dc.identifier.issue5
dc.identifier.other2446-10
dc.identifier.spage463
dc.identifier.urihttps://oarep.usim.edu.my/handle/123456789/9313
dc.identifier.volume26
dc.language.isoenen_US
dc.publisherJohn Wiley & Sons, Inc.en_US
dc.relation.ispartofNephrologyen_US
dc.subjectcost implication, diagnostic algorithm, haemodialysis, HCV core antigen, hepatitis C virusen_US
dc.titleHepatitis C Virus Core Antigen As Alternative Diagnostic Algorithm For Active Hepatitis C Virus Infection Among Haemodialysis Population: Cost Implicationsen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files

Collections

Scopus